,8,35,36 In the phase II trial with imatinib in PDGFRB/PDGFB-expressing chordomas, the clinical benefit rate (CBR) (CR + PR + SD per RECIST) was 64% after 6 months, with 1 PR and 30 SDs and a median PFS of 9 months. Here, PDGFRB is linked to chordoma.